Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis

Sameer A Parikh, Prashant Kapoor, Louis Letendre, Shaji K Kumar, Alexandra P. Wolanskyj

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Objective: To describe the prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis (HLH), a rare disorder caused by pathologic activation of the immune system. Patients and Methods: The study population consisted of a consecutive cohort of adult (age 18 years) patients treated at Mayo Clinic in Rochester, Minnesota, from January 1, 1996, through December 31, 2011, in whom a diagnosis of HLH was suspected and subsequently confirmed by retrospective review using the HLH-04 diagnostic criteria. Results: Of 250 adult patients suspected of having HLH, 62 met the HLH-04 diagnostic criteria and were included in the final analysis. The median age was 49 years (range, 18-87 years), and 42 (68%) were male. The underlying cause of HLH was malignant tumor in 32 patients (52%), infection in 21 patients (34%), autoimmune disorder in 5 patients (8%), and idiopathic disease in 4 patients (6%). After a median follow-up of 42 months, 41 patients (66%) had died. The median overall survival of the entire cohort was 2.1 months. The median overall survival of patients with tumoreassociated HLH was 1.4 months compared with 22.8 months for patients with non-tumoreassociated HLH (P=.01). The presence of a malignant tumor and hypoalbuminemia were significant predictors of inferior survival on multivariate analysis. Conclusion: In this large series of adults with secondary HLH treated at a single tertiary care center, patients with low serum albumin levels and tumoreassociated HLH had a markedly worse survival. Hemophagocytic lymphohistiocytosis remains elusive and challenging to clinicians who must maintain a high index of suspicion. The recent discovery of several novel diagnostic and therapeutic modalities may improve outcomes of adult patients with HLH.

Original languageEnglish (US)
Pages (from-to)484-492
Number of pages9
JournalMayo Clinic Proceedings
Volume89
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Hemophagocytic Lymphohistiocytosis
Survival
Hypoalbuminemia
Tertiary Care Centers
Serum Albumin
Immune System
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. / Parikh, Sameer A; Kapoor, Prashant; Letendre, Louis; Kumar, Shaji K; Wolanskyj, Alexandra P.

In: Mayo Clinic Proceedings, Vol. 89, No. 4, 2014, p. 484-492.

Research output: Contribution to journalArticle

@article{113e7e42d8bd403c8c555fd8daac42b1,
title = "Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis",
abstract = "Objective: To describe the prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis (HLH), a rare disorder caused by pathologic activation of the immune system. Patients and Methods: The study population consisted of a consecutive cohort of adult (age 18 years) patients treated at Mayo Clinic in Rochester, Minnesota, from January 1, 1996, through December 31, 2011, in whom a diagnosis of HLH was suspected and subsequently confirmed by retrospective review using the HLH-04 diagnostic criteria. Results: Of 250 adult patients suspected of having HLH, 62 met the HLH-04 diagnostic criteria and were included in the final analysis. The median age was 49 years (range, 18-87 years), and 42 (68{\%}) were male. The underlying cause of HLH was malignant tumor in 32 patients (52{\%}), infection in 21 patients (34{\%}), autoimmune disorder in 5 patients (8{\%}), and idiopathic disease in 4 patients (6{\%}). After a median follow-up of 42 months, 41 patients (66{\%}) had died. The median overall survival of the entire cohort was 2.1 months. The median overall survival of patients with tumoreassociated HLH was 1.4 months compared with 22.8 months for patients with non-tumoreassociated HLH (P=.01). The presence of a malignant tumor and hypoalbuminemia were significant predictors of inferior survival on multivariate analysis. Conclusion: In this large series of adults with secondary HLH treated at a single tertiary care center, patients with low serum albumin levels and tumoreassociated HLH had a markedly worse survival. Hemophagocytic lymphohistiocytosis remains elusive and challenging to clinicians who must maintain a high index of suspicion. The recent discovery of several novel diagnostic and therapeutic modalities may improve outcomes of adult patients with HLH.",
author = "Parikh, {Sameer A} and Prashant Kapoor and Louis Letendre and Kumar, {Shaji K} and Wolanskyj, {Alexandra P.}",
year = "2014",
doi = "10.1016/j.mayocp.2013.12.012",
language = "English (US)",
volume = "89",
pages = "484--492",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "4",

}

TY - JOUR

T1 - Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis

AU - Parikh, Sameer A

AU - Kapoor, Prashant

AU - Letendre, Louis

AU - Kumar, Shaji K

AU - Wolanskyj, Alexandra P.

PY - 2014

Y1 - 2014

N2 - Objective: To describe the prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis (HLH), a rare disorder caused by pathologic activation of the immune system. Patients and Methods: The study population consisted of a consecutive cohort of adult (age 18 years) patients treated at Mayo Clinic in Rochester, Minnesota, from January 1, 1996, through December 31, 2011, in whom a diagnosis of HLH was suspected and subsequently confirmed by retrospective review using the HLH-04 diagnostic criteria. Results: Of 250 adult patients suspected of having HLH, 62 met the HLH-04 diagnostic criteria and were included in the final analysis. The median age was 49 years (range, 18-87 years), and 42 (68%) were male. The underlying cause of HLH was malignant tumor in 32 patients (52%), infection in 21 patients (34%), autoimmune disorder in 5 patients (8%), and idiopathic disease in 4 patients (6%). After a median follow-up of 42 months, 41 patients (66%) had died. The median overall survival of the entire cohort was 2.1 months. The median overall survival of patients with tumoreassociated HLH was 1.4 months compared with 22.8 months for patients with non-tumoreassociated HLH (P=.01). The presence of a malignant tumor and hypoalbuminemia were significant predictors of inferior survival on multivariate analysis. Conclusion: In this large series of adults with secondary HLH treated at a single tertiary care center, patients with low serum albumin levels and tumoreassociated HLH had a markedly worse survival. Hemophagocytic lymphohistiocytosis remains elusive and challenging to clinicians who must maintain a high index of suspicion. The recent discovery of several novel diagnostic and therapeutic modalities may improve outcomes of adult patients with HLH.

AB - Objective: To describe the prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis (HLH), a rare disorder caused by pathologic activation of the immune system. Patients and Methods: The study population consisted of a consecutive cohort of adult (age 18 years) patients treated at Mayo Clinic in Rochester, Minnesota, from January 1, 1996, through December 31, 2011, in whom a diagnosis of HLH was suspected and subsequently confirmed by retrospective review using the HLH-04 diagnostic criteria. Results: Of 250 adult patients suspected of having HLH, 62 met the HLH-04 diagnostic criteria and were included in the final analysis. The median age was 49 years (range, 18-87 years), and 42 (68%) were male. The underlying cause of HLH was malignant tumor in 32 patients (52%), infection in 21 patients (34%), autoimmune disorder in 5 patients (8%), and idiopathic disease in 4 patients (6%). After a median follow-up of 42 months, 41 patients (66%) had died. The median overall survival of the entire cohort was 2.1 months. The median overall survival of patients with tumoreassociated HLH was 1.4 months compared with 22.8 months for patients with non-tumoreassociated HLH (P=.01). The presence of a malignant tumor and hypoalbuminemia were significant predictors of inferior survival on multivariate analysis. Conclusion: In this large series of adults with secondary HLH treated at a single tertiary care center, patients with low serum albumin levels and tumoreassociated HLH had a markedly worse survival. Hemophagocytic lymphohistiocytosis remains elusive and challenging to clinicians who must maintain a high index of suspicion. The recent discovery of several novel diagnostic and therapeutic modalities may improve outcomes of adult patients with HLH.

UR - http://www.scopus.com/inward/record.url?scp=84898886282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898886282&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2013.12.012

DO - 10.1016/j.mayocp.2013.12.012

M3 - Article

VL - 89

SP - 484

EP - 492

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 4

ER -